Key facts: GSK Increases Treasury Shares; Partners with AN2 on TB Drug; Announces Block Listing
On November 12, 2025, GSK plc bought 8,496,000 shares, increasing its treasury shares to 255,960,844, which is 6.31% of total voting rights.1AN2 Therapeutics collaborates with GSK to develop boron-based LeuRS inhibitors for tuberculosis, supported by a third year of funding from the Gates Foundation.2On November 12, 2025, GSK PLC announced its block listing six monthly return, detailing its compliance and engagement with the London Stock Exchange.3
TradingView·